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ABSTRACT
Chest pain and coronary artery disease (CAD) impose a substantial burden on public health and society. 
Diagnostic imaging tests are used by clinicians to identify the presence and extent of epicardial coronary 
disease and/or its consequences, including ischaemia, infarction, and left ventricular dysfunction.
In this article, we discuss current practice guideline recommendations for the diagnosis and management 
of patients with suspected or known CAD, and the need for more evidence from clinical trials. We then 
focus on the recently published and ongoing multicentre clinical trials of imaging-based strategies for the 
diagnosis and management of ischaemic heart disease, and the potential future impact of these trials on 
clinical practice. The results of these trials have the potential to bring radical changes to the practice of 
cardiology in the future. 
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INTRODUCTION
Coronary artery disease (CAD) is an important 
global public health burden, with a mortality 
rate of 1.2–2.4% per annum.1 The diagnosis of 
ischaemic heart disease (IHD) in patients with 
stable symptoms can be challenging because of 
variations in the pre-test probability of CAD, as well 
as the accuracy, cost, and availability of diagnostic 
tests and related management strategies.2,3 New 
diagnostic imaging-guided strategies have emerged 
for the detection and management of stable CAD, 
and gaps in clinical evidence for these diagnostic 
approaches contribute to important differences in 
global clinical practice.1,4 In this article, we briefly 
review contemporary practice and knowledge gaps 
around the diagnosis and management of patients 
with suspected or known CAD. We then focus on 
recently published and ongoing clinical trials in 
this area, and their potential impact on clinical 
practice in the future.
CLINICAL CONTEXT 
Functional stress testing, mainly with 
electrocardiogram exercise treadmill testing (ETT) 
and stress myocardial perfusion scintigraphy 
(MPS), are established standard-of-care diagnostic 
tests for CAD. Technological developments now 
enable more advanced non-invasive imaging-guided 
strategies. These diagnostic approaches comprise 
functional assessments of ischaemia, including 
stress echocardiography, stress perfusion cardiac 
magnetic resonance (CMR), and stress positron 
emission tomography (PET) (Table 1).
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Alternatively, anatomical imaging of CAD with 
computed tomography coronary angiography 
(CTCA) is an emerging diagnostic option. CTCA 
may be combined with functional imaging, 
i.e. CTCA-perfusion and computed tomography-
fractional flow reserve (CT-FFR). Concordant with 
good clinical practice, clinical judgement and 
informed patient preferences are important.4
Diagnostic Uncertainties and the Justification 
for Randomised Clinical Trials 
The coronary artery disease hypothesis  
and anatomical imaging 
The ‘CAD hypothesis’ states that detection of 
epicardial CAD through coronary artery imaging 
enables risk stratification for therapy, including 
non-pharmacological, medical, and invasive 
intervention, leading to future health benefits.1,4 
The evidence for management strategies based on 
CAD imaging with invasive coronary angiography 
(ICA) is well established,1,4 whereas evidence is 
lacking for non-invasive imaging-guided strategies. 
This evidence gap supports the rationale for the 
ongoing and recently published randomised trials. 
Importantly, diagnostic accuracy based on visual 
interpretation of invasive angiographic images 
alone may not be appropriate due to the poor 
correlation between visually assessed angiographic 
anatomical stenosis severity and the physiological 
significance of a stenosis.5
The ischaemia hypothesis and functional testing 
Myocardial ischaemia occurs when demand for 
perfusion exceeds supply.6 Ischaemia may result 
from obstructive epicardial CAD limiting coronary 
blood flow, coronary microvascular disease (CMD) 
reducing myocardial perfusion, or systemic problems 
(e.g. anaemia or tachyarrhythmia) resulting in a 
supply-demand mismatch.7 Myocardial ischaemia 
may result in typical angina pectoris, atypical 
symptoms (e.g. exertional dyspnoea), or may be 
clinically silent.8 Ischaemia revealed by functional 
imaging is associated with an adverse long-term 
prognosis.9 The ‘ischaemia hypothesis’ supposes 
that ischaemia is an adverse prognostic attribute, 
and that reducing the ischaemic burden by medical 
therapy with or without coronary revascularisation 
will result in improved clinical outcomes, 
as observedin the COURAGE trial MPS sub-study.10,11
Anatomical versus functional tests in suspected  
or known stable coronary artery disease 
Practice guidelines now recommend anatomical 
approaches in lower-risk patients with CTCA 
and ICA in higher-risk patients, recognising that 
randomised trial evidence is limited (levels B/C).1,4 
Table 1: Sensitivity and specificity of non-invasive diagnostic tests for coronary artery disease and 
international practice guideline recommendations. 
The North American practice guideline recommendations account for the patient’s ability to exercise, the 
presence of an interpretable ECG, and an intermediate-high pre-test probability of CAD.4 
CAD: coronary artery disease; ECG: electrocardiogram; MPS: myocardial perfusion scintigraphy; 
CMR: cardiac magnetic resonance; PET: positron emitting tomography; CTCA: computed tomography 
coronary angiography. 
Adapted with permission from Montalescot et al.1
Diagnosis of CAD European guideline American guideline
Sensitivity (%) Specificity (%) Class Level of evidence Class
Level of 
evidence
Exercise ECG 
Exercise stress echocardiography
Exercise stress MPS 
Dobutamine stress echocardiography
Dobutamine stress CMR
Vasodilator stress echocardiography
Vasodilator stress MPS 
Vasodilator stress CMR
CTCA
Vasodilator stress PET
45–50
80–85
73–92
79–83
79–88
72–79
90–91
67–94
95–99
81–97
85–90
80–88
63–87
82–86
81–91
92–95
75–84
61–85
64–83
74–91
1 (15–65%)
1
1
1
1
1
1
1
2a (15–50%)
1
B
B
B
B
B
B
B
B
B
B
1
2b
2a
3
3
3
3
3
2b
N/A
A
C
B
C
C
C
C
C
B
N/A
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The ideal non-invasive diagnostic test would 
have high spatial resolution (for coronary lesions, 
perfusion, or ischaemic defects), allow quantitative 
assessment of ischaemia severity, avoid or minimise 
ionising radiation exposure (concordant with the 
principle of ‘As Low As Reasonably Achievable’), 
and provide additional diagnostic information such 
as assessment of myocardial function and scarring.
CONTEMPORARY PRACTICE GUIDELINES
FOR STABLE CORONARY ARTERY
DISEASE AND THE NEED FOR MORE 
CLINICAL EVIDENCE 
European guidelines do not recommend non- 
invasive diagnostic tests in patients with a pre-test 
probability of CAD <15% or >85%.1 The UK National 
Institute of Clinical Excellence (NICE) guidelines 
recommend that diagnostic testing is not indicated 
in chest pain patients with a pre-test probability of 
CAD <10%.12 In very low-likelihood groups, medical 
management is recommended, whereas in the 
high-likelihood groups, ICA is suggested. ETT 
has been omitted and replaced with CT calcium 
scoring±CTCA for low-risk patients (given the 
high sensitivity and negative predictive value, 
but relatively lower specificity, of CTCA), and 
non-invasive stress imaging with echocardiography, 
MPS, or CMR in intermediate pre-test risk.
Estimates of obstructive CAD are based on 
historical data, which potentially overestimate risk, 
and European guidelines may increase the rate of 
unnecessary ICA.13,14 Since CAD is endemic in many 
developed countries, routine CTCA in adults with 
chest pain will commonly disclose CAD and result 
in ICA. The presence of CAD does not equate to 
causality, and non-cardiac causes of chest pain 
may coexist. This supports the case for ischaemia 
testing invasively (i.e. FFR) or non-invasively 
(i.e. CT-FFR or stress imaging).
Attributes and Limitations of Imaging  
Strategy Trials 
There is uncertainty surrounding the comparative 
effectiveness of imaging-based diagnostic 
strategies for the detection and management of 
CAD. This lack of evidence underpins the rationale 
for several large clinical trials that have recently 
reported or are ongoing. The trials may be 
summarised as:
• Trials designed to assess the most effective 
imaging strategy for the diagnosis and 
management of suspected angina (anatomical 
versus functional imaging-guided strategies, 
and non-invasive versus invasive strategies)
• Trials designed to assess the health outcomes  
of invasive management versus  
medical management
TRIALS OF THE STRATEGIES  
Detection of Coronary Artery Disease and 
Diagnosis of Angina in Patients with Chest 
Pain of Suspected Cardiac Origin 
SCOT-HEART trial 
The SCOT-HEART trial is a multicentre randomised 
controlled trial of 4,138 patients referred from 
primary care to a cardiology clinic for chest pain 
assessment. SCOT-HEART evaluated the role 
of routine CTCA in addition to standard care 
(typically with ETT) versus standard care alone in 
the investigation and risk assessment of patients 
with suspected angina.15 SCOT-HEART16 assessed 
whether anatomical delineation of the presence 
or absence of obstructive or non-obstructive CAD 
alters the diagnosis, management, and outcomes 
of patients with chest pain attending a rapid access 
chest pain clinic. Patients aged 18–75 years were 
randomised (1:1) to standard care, or standard 
care plus coronary artery calcium scoring and 
CTCA. Eligibility criteria were not restricted by the  
pre-test likelihood of CAD or a prior history of CAD, 
so patients with any pre-test risk may have been 
enrolled. Also, angina class was not an eligibility 
criterion, thus patients with crescendo or unstable 
angina may have been included. The primary 
outcome was the certainty of the diagnosis of 
angina secondary to CAD at 6 weeks.
The primary outcome was increased in the group 
randomised to CTCA (relative risk: 1.79, 95% 
confidence interval: 1.62–1.96). At 6 weeks, CTCA 
reclassified the diagnosis of CAD in 27% of patients, 
and the diagnosis of angina due to CAD in 23%. 
At 1.7-year follow-up, there was a trend towards 
a reduction in fatal and non-fatal myocardial 
infarction (MI) with CTCA, but this did not reach 
significance (p=0.0527, absolute difference between 
the groups: 16 events). Longer-term follow-up 
is planned for 5 years. Figure 1 presents a patient 
case study from this trial.
By design, SCOT-HEART did not have 
concealment of the diagnostic intervention, 
and consequently the management and outcomes 
were susceptible to unmeasured confounding. 
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The trial was not powered for health outcomes and 
the event rate was low (1.6% rate of death or MI at 
1.7-year follow-up), indicating that the results are 
hypothesis-generating, and the 5-year outcomes 
are eagerly anticipated. Routine CTCA in this 
strategy is anticipated to be associated with 
increased costs, predominantly related to the cost 
of the scan. Information on quality of life and the 
health economic analysis are awaited.17
CEMARC 2 TRIAL 
The CEMARC 2 trial is a prospective multicentre, 
three-arm parallel group, randomised controlled 
trial of routine functional imaging versus guideline-
based management.18,19 CEMARC 2 randomised 
1,202 patients (2:2:1) to 3.0 Tesla stress perfusion 
CMR, MPS (according to American College of 
Cardiology [ACC]/American Heart Association 
[AHA] appropriate-use criteria), or to management 
based on the pre-test probability of CAD 
(CT calcium scoring±CTCA: 10–29%; MPS: 30–60%; 
ICA: 61–90%), concordant with UK NICE guidelines.12 
Patients aged >30 years with known or suspected 
angina and a pre-test likelihood of CAD 10–90% 
were enrolled. The primary outcome is the 
occurrence of unnecessary invasive angiography, 
with secondary outcomes including a major 
Figure 1: Computed tomography of a SCOT-HEART trial participant.
A 60-year-old male presented to the rapid access chest pain clinic with a history of typical angina. He had 
no risk factors for CAD. A treadmill exercise tolerance test was interpreted to be positive for myocardial 
ischaemia. As part of the SCOT-HEART trial, he underwent computed tomography imaging with a 320 
multi-detector scanner using iterative reconstruction. A non-contrast scan was performed to assess 
coronary artery calcification. A) The Agatston coronary artery calcium score was 51 Agatston units. CTCA 
identified mild calcified and non-calcified atherosclerotic plaque in the left anterior descending artery 
(arrows). B) Shows axial images of the left anterior descending artery at the same position as the non-
contrast images, and curved planar reformations are shown of: C) the left anterior descending artery, D) 
the right coronary artery, and E) the left circumflex artery. Despite these reassuring findings, the attending 
clinician still referred the patient for invasive coronary angiography because of ongoing symptoms. There 
was no angiographic evidence of CAD and the patient has had uncomplicated progress on medical therapy. 
This case provides an example in which the exercise ECG overestimated the likelihood of CAD and CTCA 
might have prevented the requirement for invasive investigations.
CTCA: computed tomography coronary angiography; ECG: electrocardiogram; CAD: coronary 
artery disease.
This case was kindly provided by Dr Michelle Williams, Clinical Research Fellow, and Prof David Newby, 
Principal Investigator for the SCOT-HEART trial.
A C D E
B
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cardiovascular event (MACE) at 1 and 3 years, and 
a cost-effectiveness analysis. Unnecessary ICA is 
defined as: i) negative FFR (>0.80) and a positive 
non-invasive test (i.e. false-positive test result); 
ii) negative FFR with a high pre-test probability 
(61–90%) proceeding directly to ICA in the NICE 
guidelines-based group (i.e. false-positive for the 
strategy); iii) negative FFR and a negative non-
invasive test (i.e. true-negative strategy result 
where the imaging result was ‘not believed’ by the 
treating cardiologist [intention-to-treat principles]); 
iv) negative FFR and an inconclusive non-invasive 
test in which angiography was performed to make 
the diagnosis (i.e. failure of the strategy to produce 
a diagnosis).
The primary outcome occurred in 69 (28.8%) 
patients in the NICE guideline-managed group, and 
36 (7.5%) and 34 (7.1%) in the CMR and MPS groups, 
respectively. There was a statistically significant 
lower adjusted odds ratio (OR) of unnecessary 
angiography in the CMR versus NICE guidelines 
group (OR: 0.21, p<0.001), with no difference 
between the CMR or MPS group (OR: 1.27, p=0.32). 
There was a trend towards a reduction in the 
secondary outcome of MACE at 12 months in the 
NICE guidelines group (1.7%), compared to the CMR 
(2.5%) and MPS (2.5%) groups, but this was not 
statistically significant. CEMARC 2 demonstrates a 
significant reduction in unnecessary angiography 
with a CMR-guided strategy. The NICE guideline-
based strategy resulted in significantly more 
unnecessary invasive angiograms. Future guidelines 
may utilise improved risk stratification models.20
In contrast, a strategy of stress PET imaging has 
high diagnostic accuracy for CAD. The PACIFIC 
trial results were presented in August 2016 but are 
not yet published.21 PACIFIC enrolled 208 patients 
from a single centre referred for ICA following a 
first-presentation with chest pain secondary to 
suspected CAD. Participants had an intermediate 
pre-test likelihood of CAD and were aged >40 
years. All patients underwent ICA with FFR 
measurement to define flow-limiting epicardial 
CAD. Patients then underwent stress PET, MPS, or 
CTCA alone, with some patients undergoing hybrid 
anatomical/functional imaging with PET/CTCA or 
MPS/CTCA. The diagnostic accuracy of PET (85%) 
was significantly greater than MPS (77%, p<0.01) 
and CTCA (74%, p<0.01), with no improvement 
in diagnostic accuracy with the hybrid imaging 
approaches. PACIFIC confirmed the high diagnostic 
accuracy of stress PET imaging, however there is 
generally limited access to this modality worldwide.
Management Strategies Involving Imaging of 
Coronary Anatomy Versus Functional Testing 
in Patients with Low-Intermediate Likelihood 
of Coronary Disease
PROMISE  trial 
PROMISE was an open-label multicentre imaging 
study comparing CTCA versus non-invasive 
functional stress testing (ETT, MPS, or stress 
echocardiography) in 10,003 patients with chest 
pain due to known or suspected angina.22,23 
PROMISE tested the hypothesis that an initial 
anatomical testing strategy would inform 
subsequent patient management resulting in 
superior long-term health outcomes, as compared 
to an initial functional testing strategy. 
The functional test was selected at the clinician’s 
discretion, and may have reflected local availability. 
The primary outcome was time to the first MACE.
Compared with non-invasive functional testing, 
CTCA did not improve clinical outcomes at a median 
follow-up of 2 years compared with functional 
testing (3.3% versus 3.0%). The interpretation 
of PROMISE may be limited by the low event 
rate and relatively short follow-up period. 
Contemporary non-invasive functional tests such 
as stress perfusion CMR and PET, which have a 
higher sensitivity for detecting ischaemia, were 
not included. There was a significant difference in 
the revascularisation rates at 90 days between the 
CTCA and functional testing group (6.2% 
versus 3.2% of patients, p<0.001), however if 
functional results for ischaemia (e.g. invasive FFR) 
were lacking, the appropriateness of these 
revascularisations is uncertain. PROMISE concluded 
that either a routine functional or routine 
anatomical strategy is reasonable.17 In comparison, 
CT-FFR may allow a hybrid anatomical and 
functional imaging strategy and extend the role of 
CT-based strategies. CT-FFR is assessed using 
proprietary software which applies three- 
dimensional blood flow simulations using the 
principles of computational fluid dynamics.24,25 
RESCUE  trial
The RESCUE study26 is a multicentre randomised 
controlled trial of 4,300 patients, comparing two 
different diagnostic imaging modalities: CTCA 
versus MPS. In addition, building on the results 
of the COURAGE trial,11 all patients without 
evidence of left main stem disease will be 
treated with optimal medical therapy (OMT). The 
primary endpoint is a combination of MACE and 
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revascularisation. It is hypothesised that CTCA 
is cheaper and patients will be exposed to less 
radiation with no increase in the rate of MACE or 
revascularisation, with a 24-month follow-up. On 
27 October 2014 the study was terminated because 
the funding timeline had completed. By September 
2014, 1,050 participants had been randomised. 
No further information is available at this time.
CARE-CTCA  trial
The CARE-CTCA trial is a multicentre randomised 
trial of 1,050 patients investigating the cost-
effectiveness and health outcomes of a CTCA 
versus MPS-guided management strategy in 
patients with an intermediate risk of CAD.27 
Patients aged 30–80 years with an intermediate 
probability of CAD will be randomised (1:1) to either 
CTCA or MPS. The primary outcome is a cost-
effectiveness analysis at 1 year.
Taken together, the results of these ongoing trials26-28 
will provide information on whether or not a CTCA-
guided approach improves symptoms, prognosis, 
and cost-effectiveness compared to functional 
approaches, in which MPS will likely be used in the 
majority of the participants. 
Non-Invasive Imaging Versus Invasive 
Coronary Angiography in Patients with 
Intermediate-High Likelihood of Coronary 
Artery Disease 
MR-INFORM  trial
MR-INFORM is a multicentre randomised controlled 
non-inferiority trial designed to compare 1.5 Tesla 
stress CMR to routine ICA with FFR measurement, 
in order to guide revascularisation in patients with 
stable angina.29 MR-INFORM participants would be 
eligible for ICA based on clinical criteria concordant 
with clinical guidelines.1,12 The trial includes 918 
patients who will undergo perfusion CMR prior to 
angiography, and will then be randomised (1:1) to 
either CMR-guided management or FFR-guided 
management (perfusion CMR result not disclosed) 
of intermediate angiographic lesions (≥40% to <99% 
severity). Inclusion criteria are age >18 years, typical 
angina, plus ≥2 cardiac risk factors, or positive ETT. 
Figure 2 presents a patient case study from this trial.
MR-INFORM hypothesises that in patients with 
a high likelihood of CAD, management based on 
a functional test without knowledge of coronary 
anatomy could be an acceptable alternative 
approach to invasive management. MR-INFORM 
will provide further evidence on the safety and 
efficacy of perfusion CMR in the investigation of 
CAD. By design, CEMARC 2 involved a lower-risk 
patient population than MR-INFORM and so these 
trials should provide complementary information. 
In contrast to these functional strategies, the 
DISCHARGE study tests the hypothesis that an 
anatomical CTCA-guided strategy is superior to 
ICA in patients with a low-to-intermediate pre-test 
likelihood of CAD.30 DISCHARGE will randomise 
(1:1) 3,546 patients with stable chest symptoms, 
aged >30 years, and with a pre-test likelihood of 
CAD of 10–60%, to CTCA or ICA. The enrolment 
period will be 2 years and the maximum follow-up 
is 4 years. DISCHARGE is a superiority trial and the 
primary outcome measure is major adverse cardiac 
and cerebrovascular events. Secondary outcomes 
include symptoms, quality of life, and cost-
effectiveness. Contemporary practice guidelines 
do not recommend routine invasive angiography 
as a first-line test in patients with a pre-test CAD 
likelihood of 10–60%, yet this is the likelihood range 
for inclusion in this trial. 
Non-Invasive Versus Invasive Management 
of Symptomatic Patients with Non-Invasive 
Evidence of Moderate-Severe Ischaemia 
ISCHEMIA trial 
The ISCHEMIA trial is a multicentre randomised 
controlled trial of 8,000 patients.31,32 It tests the 
hypothesis that an initial strategy of ICA followed by 
percutaneous coronary intervention (PCI) if feasible, 
in addition to OMT, will reduce the composite 
primary endpoint of cardiovascular death or non-
fatal MI in patients with at least moderate ischaemia 
on stress imaging (echocardiography, MPS, or 
CMR), compared with an initial conservative strategy 
of OMT alone, with ICA reserved for failure of OMT.
International guidelines recommend that 
revascularisation is targeted towards relieving 
ischaemia rather than anatomical lesions in the 
epicardial coronary arteries.33,34 Anatomical 
assessments of CAD alone are inadequate to 
accurately identify functionally significant disease.35 
The results of the FAME and FAME-2 trials indicate 
that patients with symptoms and ischaemia 
(FFR ≤0.8) derive prognostic benefits from PCI 
versus medical therapy alone,36,37 whereas those 
with functionally insignificant lesions (FFR >0.8) 
do not. FAME-2 supports the validity of the 
ischaemia hypothesis, however this trial was not 
designed or powered to provide information on 
the ‘hard’ spontaneous outcomes of death or MI. 
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The ISCHEMIA trial will further inform the 
hypothesis that invasive management with 
clinically-indicated revascularisation may improve 
health outcomes in patients with stable CAD and a 
moderate-to-large ischaemic burden, compared to 
OMT. The ISCHEMIA trial has pivotal importance for 
the future management of CAD.
The ISCHEMIA-CKD32 sub-study investigates the 
same questions as the ISCHEMIA trial but in 
patients with advanced renal disease, a group of 
patients that is particularly challenging to diagnose 
and manage effectively and safely.
Anatomical Imaging and Coronary 
Microvascular Disease 
PROMISE enrolled 10,003 patients, with 1,015 
undergoing diagnostic ICA within 90 days of 
randomisation.23 A predefined secondary endpoint 
of non-obstructive CAD on ICA occurred in 3.4% of 
the CTCA group and 4.3% in the functional testing 
group (p=0.02). Does this cohort with anginal 
symptoms and non-obstructive CAD (some with 
positive non-invasive stress testing) represent 
patients with a non-cardiac aetiology for their 
symptoms, false-positive non-invasive stress testing, 
or might CMD contribute? Angina may occur in 
Figure 2: Magnetic resonance imaging of a MR-INFORM trial participant. 
A 61-year-old female cigarette smoker with a history of symptoms consistent with angina was referred 
by her primary care physician for out-patient cardiology investigations. Based on this history, the pre-test 
probability of CAD was estimated to be 68% and a referral for invasive coronary angiography was made 
in line with contemporary guidelines. The woman fulfilled the eligibility criteria for MR-INFORM and, 
based on informed consent, she was randomised to the MR-guided group. CMR cine imaging revealed 
A) normal left ventricular systolic function, and compared with first-pass CMR imaging at rest; 
B) adenosine stress perfusion CMR; C) revealed a circumferential subendocardial inducible perfusion 
defect; D) the absence of late gadolinium enhancement imaging ruled out an infarct scar; E and F) invasive 
coronary angiography revealed minimal non-obstructive CAD. A diagnosis of microvascular angina was 
established and she was treated with 20 mg of isosorbide mononitrate twice daily, 75 mg of aspirin 
daily, and 40 mg of simvastatin daily.
CMR: cardiac magnet resonance; CAD: coronary artery disease.
Reproduced with permission from Dr David Carrick, Golden Jubilee National Hospital, Glasgow, and Prof 
Eike Nagel, principal investigator for the MR-INFORM trial. 
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the absence of flow-limiting epicardial CAD. In this 
situation, patients may receive no further diagnostic 
testing and be reassured that they have a non- 
cardiac cause for their symptoms. However, a 
significant number may have coronary CMD and 
‘microvascular angina’.38 In comparison to the 
literature concerned with epicardial CAD, there 
is a nascent evidence-base for the diagnosis and 
therapeutic interventions in coronary CMD.
There is no available technique which allows direct 
visualisation of the coronary microcirculation 
in vivo. Increasing use of invasive diagnostic tests to 
assess parameters of coronary physiology (coronary 
pressure, flow, and microvascular resistance) are 
providing new, clinically relevant diagnostic and 
prognostic information.39 Additionally, coronary 
endothelial dysfunction may result in angina which 
may be evaluated with vaso-reactivity testing.40 
These observations have challenged the dogma 
that IHD equates to obstructive epicardial CAD.41 
Non-invasive functional tests have lower sensitivity 
and specificity for CMD, although the kinetics and 
distribution of perfusion abnormalities revealed by 
stress perfusion CMR can be diagnostic. A limitation 
of the CAD hypothesis is that anatomical diagnostic 
tests, such as CTCA, are of limited value for the 
diagnosis of microvascular angina. There are several 
comparatively small multi-modality imaging studies 
in patients with microvascular angina, including 
iPOWER,42 however large randomised trials of 
therapeutic interventions are lacking. In summary, 
reflecting the heterogeneous causes of angina, we 
propose ‘stable coronary artery syndrome’ as a new 
unifying diagnostic term.
Summary of Imaging Studies 
Clinical trials also have limitations; trials involve 
patient selection that commonly excludes real-
world patients with multi-morbidity and advanced 
disease (e.g. patients with advanced renal disease 
in CMR trials). The timing of randomisation is also 
key; randomisation performed close to the time 
of consent and prior to diagnostic testing should 
lead to enrolment of a study population more 
representative of real-world patients compared 
to randomisation performed downstream. 
Other important design considerations include 
concealment of treatment allocation, as this may 
lead to a falsely enhanced magnitude of treatment 
effect43 and blinded and independent assessment of 
primary and secondary outcomes.
TRENDS IN CURRENT PRACTICE AND 
FUTURE DIRECTIONS 
An analysis of 397,954 patients with chest pain and 
no history of CAD who underwent ICA found that 
only 37.6% had angiographic evidence of epicardial 
CAD, whilst 39.2% had no epicardial CAD.44 This 
calls into question the initial diagnostic basis for 
referral, and also the work-up for CMD if obstructive 
epicardial CAD is excluded. Adoption of non-
invasive and invasive tests of flow-limiting coronary 
disease has increased since these results emerged. 
Key questions around the roles of anatomical and 
functional testing and non-invasive versus invasive 
management are being prospectively assessed in 
large clinical trial populations. The current clinical 
guideline recommendations that are not supported 
by randomised trial evidence (i.e. level C for CTCA 
recommendations)1,4 are currently subject to 
prospective assessment. Finally, a doctor’s clinical 
opinion should be individualised to the patient, who 
is entitled to have options wherever possible to 
enable an informed decision.
CONCLUSION 
The current diagnostic trials in stable CAD involve 
>30,000 patients globally. The ongoing trials are 
expected to report within the next 5–7 years and, 
depending on their results, the trials have the 
potential to bring radical changes to the practice 
of cardiology. A recognition that stable IHD may 
not only be due to obstructive epicardial CAD, 
but also to coronary microvascular and vasomotor 
abnormalities, may prompt further research into 
non-invasive functional testing. Anatomical and 
functional non-invasive imaging in epicardial and 
microvascular CAD will ultimately need to be 
demonstrated to improve health outcomes to enter 
daily clinical practice.
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